X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10637) 10637
Newsletter (275) 275
Newspaper Article (147) 147
Magazine Article (31) 31
Book Chapter (25) 25
Dissertation (17) 17
Publication (6) 6
Government Document (4) 4
Conference Proceeding (3) 3
Report (2) 2
Book / eBook (1) 1
Streaming Video (1) 1
Transcript (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7302) 7302
female (7273) 7273
tamoxifen (6873) 6873
oncology (4122) 4122
breast neoplasms - drug therapy (3983) 3983
breast cancer (3981) 3981
middle aged (3274) 3274
tamoxifen - administration & dosage (2999) 2999
animals (2667) 2667
aged (2426) 2426
adult (2281) 2281
tamoxifen - therapeutic use (2258) 2258
cancer (2132) 2132
breast neoplasms - pathology (1887) 1887
tamoxifen - pharmacology (1834) 1834
postmenopausal women (1705) 1705
antineoplastic combined chemotherapy protocols - therapeutic use (1612) 1612
estrogen (1482) 1482
male (1426) 1426
care and treatment (1374) 1374
research (1348) 1348
mice (1316) 1316
chemotherapy (1289) 1289
antineoplastic agents, hormonal - therapeutic use (1240) 1240
treatment outcome (1233) 1233
therapy (1138) 1138
women (1138) 1138
chemotherapy, adjuvant (1070) 1070
rats (1034) 1034
tamoxifen - adverse effects (1029) 1029
health aspects (1017) 1017
antineoplastic agents, hormonal - administration & dosage (996) 996
drug therapy (915) 915
pharmacology & pharmacy (911) 911
medicine & public health (906) 906
expression (874) 874
breast neoplasms - metabolism (845) 845
breast-cancer (820) 820
prevention (810) 810
analysis (799) 799
postmenopause (799) 799
endocrine therapy (796) 796
risk factors (785) 785
aged, 80 and over (782) 782
prognosis (765) 765
breast neoplasms - surgery (739) 739
breast neoplasms - mortality (735) 735
aromatase inhibitors (727) 727
drug administration schedule (717) 717
randomized-trial (671) 671
receptors, estrogen - metabolism (662) 662
menopause (651) 651
dosage and administration (636) 636
dose-response relationship, drug (635) 635
time factors (633) 633
obstetrics & gynecology (631) 631
disease-free survival (628) 628
anastrozole (613) 613
combined modality therapy (603) 603
breast neoplasms - genetics (599) 599
antineoplastic agents, hormonal - adverse effects (595) 595
follow-up studies (584) 584
neoplasm staging (578) 578
cyclophosphamide - administration & dosage (568) 568
letrozole (546) 546
tumors (539) 539
fluorouracil - administration & dosage (530) 530
risk (529) 529
apoptosis (522) 522
estrogen-receptor (518) 518
estradiol - pharmacology (517) 517
antineoplastic agents - therapeutic use (508) 508
breast neoplasms - therapy (503) 503
oncology, experimental (500) 500
tamoxifen - analogs & derivatives (500) 500
breast neoplasms - prevention & control (498) 498
cell line, tumor (487) 487
clinical trials as topic (487) 487
surgery (480) 480
trial (479) 479
aromatase inhibitors - therapeutic use (477) 477
estrogen antagonists - pharmacology (477) 477
endocrinology & metabolism (476) 476
gene expression (467) 467
survival (466) 466
survival analysis (446) 446
cells (442) 442
research article (440) 440
carcinoma (436) 436
receptors, estrogen - analysis (433) 433
clinical trials (432) 432
growth (423) 423
adjuvant treatment (421) 421
randomized controlled trials as topic (420) 420
administration, oral (419) 419
survival rate (409) 409
antineoplastic combined chemotherapy protocols - adverse effects (406) 406
cell biology (401) 401
ovariectomy (398) 398
retrospective studies (396) 396
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10706) 10706
Japanese (253) 253
French (100) 100
German (96) 96
Russian (47) 47
Italian (21) 21
Portuguese (18) 18
Chinese (15) 15
Spanish (13) 13
Polish (9) 9
Hungarian (7) 7
Korean (5) 5
Czech (4) 4
Danish (4) 4
Norwegian (4) 4
Swedish (4) 4
Dutch (3) 3
Romanian (3) 3
Persian (2) 2
Hebrew (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology, ISSN 0923-7534, 2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2008, Volume 9, Issue 9, pp. 840 - 849
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9707, pp. 2055 - 2063
Summary Background Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of... 
Internal Medicine | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | THERAPY | CYCLOPHOSPHAMIDE | METHOTREXATE | ANTAGONISM | CARCINOMA | FLUOROURACIL CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Lymph Nodes - pathology | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Alkylating - administration & dosage | Tamoxifen - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Receptors, Progesterone - analysis | Fluorouracil - administration & dosage | Postmenopause | Adult | Female | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Adenocarcinoma - mortality | Adjuvant treatment | Breast cancer | Dosage and administration | Research | Drug therapy | Tamoxifen | Health aspects | Cancer | Heart failure | Chemotherapy | Womens health | Mortality | Clinical trials | Mammography | Radiation therapy | Cancer therapies | Tumors | Toxicity | Leukemia | Congestive heart failure | Doxorubicin | Evidence-based medicine | Subgroups | Rank tests | Randomization | Motivation | Registration | Mastectomy | Thromboembolism | Neutropenia | Review boards | Regression analysis | Patients | Survival | Post-menopause | Stomatitis | Cyclophosphamide | Anthracycline | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 766 - 776
This study of adjuvant hormonal therapy in postmenopausal women with hormone-receptor–positive early breast cancer showed that disease-free survival was... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | EXEMESTANE | CONTINUED TAMOXIFEN | ADJUVANT ENDOCRINE THERAPY | RANDOMIZED-TRIAL | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ANASTROZOLE | Aromatase Inhibitors - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Fractures, Bone - epidemiology | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Incidence | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Nitriles - adverse effects | Women | Care and treatment | Usage | Breast cancer | Tamoxifen | Comparative analysis | Health aspects | Drug therapy | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus | Hormonal | Breast Neoplasms | epidemiology | administration & dosage | Triazoles | Nitriles | Adjuvant | drug therapy | Antineoplastic Agents | Local | prevention & control | Aromatase Inhibitors | Chemotherapy | Fractures | adverse effects | Bone | Neoplasm Recurrence | Cancer and Oncology | Kaplan-Meiers Estimate | Cancer och onkologi
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 68 - 81
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 33, pp. 5529 - 5537
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth... 
AROMATASE INHIBITOR | OVEREXPRESSION | ONCOLOGY | SERUM HER-2/NEU | TAMOXIFEN | RESISTANCE | LETROZOLE | ENDOCRINE THERAPY | COMBINATION | HER2 | ESTROGEN-RECEPTOR | Receptors, Estrogen - blood | Triazoles - administration & dosage | Triazoles - adverse effects | Confidence Intervals | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Adenocarcinoma - metabolism | Statistics, Nonparametric | Aged, 80 and over | Female | Drug Administration Schedule | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Adenocarcinoma - secondary | Biomarkers, Tumor - blood | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Nitriles - adverse effects | Receptors, Progesterone - blood | Receptor, ErbB-2 - blood | Trastuzumab | Adenocarcinoma - mortality | Index Medicus
Journal Article